|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that adenovirus-mediated VEGF direct myocardial administration to patients with severe coronary artery disease is safe, and future larger trials are warranted to assess efficacy.
|
23137122 |
2013 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, clinical trials of VEGF gene therapy in patients with coronary artery disease or peripheral artery disease have not, to date, demonstrated clinical benefit.
|
23856679 |
2013 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VEGF gene expression is decreased in individuals with CAD+ disease.
|
22711306 |
2012 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor and its receptor the kinase domain receptor play critical roles in the pathogenesis of coronary artery disease.
|
21573804 |
2012 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Statistically significant results found for the various QTs and SNPs were: rs3774933, rs230528, rs230521, rs1005819 and rs1609798 (intronic, NFKB1) with APOB; rs5361 (Missense, R greatr than S, SELE) and rs4648004 (Intronic, NFKB1) with FBG; rs4220 (Missense, K greater than R, FGB) with HCY; and rs3025035 (Intronic, VEGFA) with CHOL-H. SNPs in SELE, VEGFA, FGB and NFKB1 genes impact significantly on levels of quantitative precursors of CAD in Marwaris.
|
22116284 |
2011 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD).
|
21252014 |
2011 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we have analyzed the effect of 1154 A/G polymorphism of VEGF and 70 bp VNTR polymorphism of intron 3 in IL-4 genes in coronary heart disease (CHD) patients (n = 300) and their age matched controls (n = 300).
|
20364398 |
2010 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The VEGF +405C/G polymorphism is a novel genetic factor to influence the extent of coronary atherosclerosis in the Chinese CAD population.
|
20489684 |
2010 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study tested the association between functional VEGF +405 C>G (rs2010963), -2578C>A (rs699947) polymorphisms, and coronary collaterals in patients with coronary artery disease (CAD).
|
20621071 |
2010 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease.
|
19544222 |
2009 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Homocysteine and MTHFR and VEGF gene polymorphisms: impact on coronary artery disease.
|
19565133 |
2009 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genotyping for VEGF gene +405 G>C polymorphism was performed in 64 patients with coronary artery disease at a mean age of 66 years (76.6% males), with a mean EuroSCORE (European System for Cardiac Operative Risk Evaluation) of 2.5 (0-2 points: 50% patients, 3-4: 25%, > or =5 points: 25%), who underwent CABG surgery.
|
19920796 |
2009 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.
|
19352324 |
2009 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease.
|
17961532 |
2008 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The gene encoding vascular endothelial growth factor (VEGF) is associated with differential protein expression and has been investigated in coronary artery disease (CAD) studies.
|
19037583 |
2008 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A significantly higher frequency of the CC genotype of the -634 C/G VEGF polymorphism was found in the patients with MI compared to the patients without CAD (17.5 vs. 9.2%; p = 0.019), whereas the insertion/deletion VEGF polymorphism failed to yield an association with MI.
|
17264508 |
2007 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) and its receptor KDR (kinase insert domain-containing receptor/fetal liver kinase-1, also called VEGFR2) play critical roles in angiogenesis and vascular repair, which are involved in the progress of coronary heart disease.
|
17707181 |
2007 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that the nonconclusive VEGF gene therapy trials chronic coronary artery disease was not due to a preexisting upregulation of VEGF in chronic ischemic myocardium.
|
16627361 |
2006 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest a crucial role of VEGF-A in the development of coronary artery disease.
|
15754021 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
LHGDN |
Our findings suggest a crucial role of VEGF-A in the development of coronary artery disease.
|
15754021 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
VEGF polymorphisms and severity of atherosclerosis.
|
15937083 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Therapeutic
|
disease |
CTD_human |
VEGF polymorphisms and severity of atherosclerosis.
|
15937083 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
|
15347709 |
2004 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, more research including large scaled clinical trials is needed before deciding whether the vascular endothelial growth factor therapy either as a gene or a recombinant slow-release protein formulation therapy can be offered to patients with severe coronary artery disease, which cannot be treated with conventional revascularization.
|
12762479 |
2003 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Catheter-based intracoronary vascular endothelial growth factor (VEGF) gene transfer is a potential treatment for coronary heart disease.
|
12742981 |
2003 |